

Ref: FOI/CAD/ID 4004

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone
Kent
ME16 9QQ

Email: mtw-tr.foiadmin@nhs.net

08 May 2017

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to HER2 Breast Cancer.

In your trust, how many patients with HER2 breast cancer are currently being treated (in the past 3 months available) with the following products;

- Herceptin IV (trastuzumab IV) only*
- Herceptin SC (trastuzumab SC) only*
- Perjeta (pertuzumab) combined with Herceptin/Docatexel*
- Kadcyla (trastuzumab emtansine)*
- Tyverb (lapatinib)*

Please see the following table:

Herceptin IV (trastuzumab IV) only	0
Herceptin SC (trastuzumab SC) only	36
Perjeta (pertuzumab) combined with Herceptin/Docatexel	4
Kadcyla (trastuzumab emtansine)	0
Tyverb (lapatinib)	0